
Viveve Medical VIVE
Quarterly report 2022-Q3
added 11-10-2022
Viveve Medical General and Administrative Expenses 2011-2026 | VIVE
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Viveve Medical
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 12.5 M | 13.7 M | 22.4 M | 38.6 M | 28.8 M | 12.9 M | 7.46 M | 4.28 M | 3.33 M | 2.63 M | 2.44 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 38.6 M | 2.44 M | 13.5 M |
Quarterly General and Administrative Expenses Viveve Medical
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 3.41 M | 3.39 M | 3.65 M | - | 2.91 M | 2.93 M | 3.58 M | - | 2.76 M | 3.35 M | 4.36 M | - | 5.03 M | 5.53 M | 6.63 M | - | 9.11 M | 9.44 M | 8.93 M | - | 7.37 M | 6.86 M | 5.45 M | - | 3.27 M | 2.62 M | 2.55 M | - | 1.76 M | 1.82 M | 1.58 M | - | 1.79 M | 812 K | 779 K | - | 532 K | 965 K | 685 K | - | 674 K | 564 K | 661 K | - | 591 K | 667 K | 593 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 9.44 M | 532 K | 3.27 M |
General and Administrative Expenses of other stocks in the Medical devices industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acutus Medical
AFIB
|
14.1 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
7.11 M | - | 3.58 % | $ 2.21 M | ||
|
AxoGen
AXGN
|
44.6 M | $ 28.6 | -1.92 % | $ 1.32 B | ||
|
GenMark Diagnostics, Inc.
GNMK
|
25.6 M | - | - | $ 1.77 B | ||
|
Alphatec Holdings
ATEC
|
499 M | $ 12.19 | -3.02 % | $ 1.83 B | ||
|
Axonics Modulation Technologies
AXNX
|
40.2 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
14.1 M | - | 1.37 % | $ 20.5 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
8.78 M | - | -5.86 % | $ 30.6 M | ||
|
Bruker Corporation
BRKR
|
894 M | $ 36.62 | -4.9 % | $ 5.46 K | ||
|
Cognyte Software Ltd.
CGNT
|
163 M | $ 8.63 | 2.92 % | $ 620 M | ||
|
Conformis
CFMS
|
28.8 M | - | - | $ 16.4 M | ||
|
Cutera
CUTR
|
63.3 M | - | -10.19 % | $ 1.99 M | ||
|
AdaptHealth Corp.
AHCO
|
382 M | $ 9.51 | -0.94 % | $ 1.29 B | ||
|
Electromed
ELMD
|
39.3 M | $ 24.0 | -1.56 % | $ 203 M | ||
|
Apollo Endosurgery
APEN
|
20.6 M | - | - | $ 475 M | ||
|
Dynatronics Corporation
DYNT
|
8.46 M | - | 14.99 % | $ 929 K | ||
|
Cardiovascular Systems
CSII
|
171 M | - | 0.15 % | $ 844 M | ||
|
CONMED Corporation
CNMD
|
132 M | $ 40.21 | -2.9 % | $ 1.25 B | ||
|
EDAP TMS S.A.
EDAP
|
5.9 M | $ 4.21 | -0.94 % | $ 157 M | ||
|
CryoLife, Inc.
CRY
|
141 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
14.1 M | - | -20.74 % | $ 369 K | ||
|
Apyx Medical Corporation
APYX
|
22.2 M | $ 3.16 | -3.07 % | $ 109 M | ||
|
Eargo
EAR
|
54.3 M | - | - | $ 10.2 M | ||
|
Soliton, Inc.
SOLY
|
8.46 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.88 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
8.5 M | - | 0.03 % | $ 1.58 B | ||
|
Second Sight Medical Products
EYES
|
806 K | - | -0.97 % | $ 54.4 M | ||
|
FONAR Corporation
FONR
|
23.5 M | $ 18.48 | -0.48 % | $ 121 M | ||
|
Accuray Incorporated
ARAY
|
47.9 M | $ 0.49 | -2.39 % | $ 50.4 M | ||
|
Misonix, Inc.
MSON
|
18 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
14.7 M | - | - | $ 111 M | ||
|
Cytosorbents Corporation
CTSO
|
35 M | $ 0.82 | 1.35 % | $ 44.6 M | ||
|
Align Technology
ALGN
|
1.76 B | $ 173.34 | -1.29 % | $ 13 B | ||
|
Intersect ENT, Inc.
XENT
|
98.6 M | - | - | $ 955 M | ||
|
Butterfly Network
BFLY
|
39.8 M | $ 3.65 | -2.93 % | $ 773 M | ||
|
BIOLASE
BIOL
|
10.2 M | - | -13.19 % | $ 166 K | ||
|
Abbott Laboratories
ABT
|
12.3 B | $ 109.92 | -0.95 % | $ 191 B | ||
|
IRadimed Corporation
IRMD
|
15.9 M | $ 98.53 | -1.57 % | $ 1.25 B | ||
|
Inogen
INGN
|
67.4 M | $ 6.46 | -1.37 % | $ 172 M | ||
|
InMode Ltd.
INMD
|
8.41 M | $ 13.26 | -1.45 % | $ 857 M | ||
|
BioSig Technologies
BSGM
|
11.6 M | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
6.89 B | $ 71.46 | -2.09 % | $ 106 B | ||
|
OrthoPediatrics Corp.
KIDS
|
120 M | $ 18.05 | 1.29 % | $ 423 M | ||
|
IRIDEX Corporation
IRIX
|
8.75 M | $ 1.24 | -10.14 % | $ 20 M | ||
|
Pulmonx Corporation
LUNG
|
102 M | $ 2.03 | 25.78 % | $ 79.4 M | ||
|
Helius Medical Technologies
HSDT
|
9.27 M | $ 2.17 | -3.55 % | $ 1.32 M | ||
|
Medtronic PLC
MDT
|
10.8 B | $ 90.96 | -2.2 % | $ 117 B | ||
|
Edwards Lifesciences Corporation
EW
|
2.09 B | $ 82.03 | -2.21 % | $ 48 B |